Usted buscó: appendix (Danés - Español)

hydro-appendix
hidroapΘndice

lymfefolliklerne i appendix vermiformis
nódulos linfáticos del apéndice vermiforme

appendix 1 netting agreements 1 .
appendix 1 netting agreements 1 .

appendix 2 transactions not subject to any netting agreement 1 .
appendix 2 transactions not subject to any netting agreement 1 .

appendiks v erstattes af følgende: » appendix v operating schedule 1.
se sustituirá el apéndice v por el siguiente: « appendix v operating schedule 1.

« appendix 2 to the design brief » , februar 1996 , 24,6 mb en
appendix 2 to the design brief , febrero de 1996 , 24,6 mb en

[11] riktlinjer för bedömningen finns i appendix a och appendix b till ices code of practice.
[11] el evaluador podrá guiarse por el apéndice a y el apéndice b del código de prácticas del ciem.

to optimise the settlement of queued payment orders , the ecb may use the optimisation procedures described in appendix i.
to optimise the settlement of queued payment orders , the ecb may use the optimisation procedures described in appendix i.

the provisions of this appendix apply to transactions entered into between the parties that are not effectively subject to any other netting agreement .
the provisions of this appendix apply to transactions entered into between the parties that are not effectively subject to any other netting agreement .

lokal vejledning i tb- screening (se risk management plan (rmp) appendix 1 for udkast til
los objetivos del programa educativo para los profesionales snaitarios estarán centrados en: • orientación local para la detección de la tuberculosis (ver bocetos de los materiales en el pgr del Ápendice 1). • los riesgos potenciales serán la parte central de este programa educativo.

2000o0001 --- da --- 15.03.2006 --- 004.001 --- 23 ▼b appendix 1 netting agreements
2000o0001 --- es --- 15.03.2006 --- 004.001 --- 24 ▼b appendix 1 netting agreements

payment orders may be moved either to the front or to the end of the respective queue with immediate effect at any time during daytime processing , as referred to in appendix v.
payment orders may be moved either to the front or to the end of the respective queue with immediate effect at any time during daytime processing , as referred to in appendix v.

concept paper on the development of an appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia
concept paper on the development of an appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia

clause 5.1 shall continue to operate to the extent possible notwithstanding the unenforceability under applicable law of any provisions contained in any netting agreement ( including under appendix 2 to this agreement ) .
clause 5.1 shall continue to operate to the extent possible notwithstanding the unenforceability under applicable law of any provisions contained in any netting agreement ( including under appendix 2 to this agreement ) .

2000o0001 --- da --- 15.03.2006 --- 004.001 --- 10 ▼b appendix 2 transactions not subject to any netting agreement 1 .
2000o0001 --- es --- 15.03.2006 --- 004.001 --- 11 ▼b appendix 2 transactions not subject to any netting agreement 1 .

adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow- acting anti- rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti- fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for baseline covariates points to consider on the clinical investigation of medicinal products in the treatment of asthma note for guidance on the clinical investigation of medicinal products for the treatment of urinary incontinence in women note for guidance on the evaluation of medicinal products for treatment of migraine appendix to the cpmp note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia, on methodology of clinical trials concerning the development of depot preparations of approved medicinal products in schizophrenia note for guidance on the evaluation of medicinal products indicated for thrombolysis in acute myocardial infarction addendum on acute cardiac failure to the cpmp note for guidance on clinical investigation of medicinal products in the treatment of acute cardiac failure note for guidance on the evaluation of medicinal products for the treatment of dyslipoproteinaemia points to consider on clinical investigation of slow-acting anti-rheumatic medicinal products in rheumatoid arthritis points to consider on irritable bowel syndrome points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications: